Hexoskin | Pierre-Alexandre Fournier, CEO

(Transcription)

Pierre-Alexandre Fournier  0:05  

Hello, my name is Pierre-Alexandre Fournier. I'm CEO and co founder of Hexoskin. Thank you for coming to my talk today. Hexoskin offers the best cardio respiratory monitoring and Diagnostic Services in the world for patients and professionals. We help professionals keep patients at home and safe. The problem we're solving is the following How do we monitor 3.7 million patients who need long term post acute cardio respiratory monitoring, we're talking about heart failure, heart attacks, COPD, lung exacerbation, or severe COVID. For example, well, hexoskin has developed a simple solution to collect vital signs data from home with a tool that any patient can be comfortable with a smart shirt that monitors continuous ECG and lung function. But let's take a step back and take a look at where excess skin is from. excess skin is the child of investment in remote patient monitoring technologies from a space agencies. Since 2019, NASA and other space agencies use our technology in the International Space Station for monitoring the health of astronauts. We've shipped nine payloads to the International Space Station so far with SpaceX and Cygnus rockets. But of course, this is a very niche market. Most of our clients today, they are using our technology to do clinical research. We allow them to record physiology in real life environments. Hundreds of organizations use existing products including over 30 US research hospitals, we've shipped almost 15,000 units so far, pre FDA clearance. Our research clients have published over 150 scientific papers, we take the scan data. But let's come back to our problem. What doctors prescribed today for home testing or adhesive based monitors, either traditional Holter monitors like the patient on the left, or ECG patches, like the one this woman just removed after one week. The expression on her face was when she realized the skin rash she got from it. This is a real patient on YouTube. The lesson here is these adhesive based products are used to monitor patients for a few days. But they were not designed to monitor patients for weeks or for months. At these days with will never work for long term monitoring. What we've done I think the skin is replacing these products with a smart shirt, simple to use, easy to put on enough and machine washable, designed for long term use. This replaces ECG Holter monitors, but also for the first time provides a Holter monitor for the lungs, which opens a whole new field in cardio respiratory monitoring. I'm wearing one of these shirts today. My vital signs are sent in real time to our servers via my smartphone. The information is then processed and the results are summarized and added to my patient file. It's very discreet. It's very comfortable. This is a product patients love. Now 2222 is a big year for Hexo skin. We filed with the FDA a year ago and we're expecting to your answer in the coming months. This will allow us to launch Hexoskin labs, a remote diagnostic lab company that will provide services that extend the current market offering for home based ECG and pulmonary monitoring. Our business model is simple. We work like a lab. No investment needed, no additional staff required. We just get the prescription for physician we fulfill the prescription and we send back the test results for physician is just like ordering bloodwork. CPT codes exist, of course, however, we work with hospitals that have separate budgets for post acute care for high value patients, and this will allow us to capture higher revenues. But there's more. We're also invested in deep in a deep digital biomarker development pipeline that goes way beyond cardiac and respiratory testing, and covers segments such as mental health, oncology and rare disease. We believe there are enough opportunities out there to build a remote diagnostic company the size of Quest Diagnostics. This is the largest opportunity in digital health right now. Our typical High Value patients will bring in between $602,000 for the service. And we're targeting a 75 to 80% Gross, gross margin on the services. Our offer, our offering is very competitive. We're being pulled very hard by our current clients. And our sales pipeline pretty much guarantees the next two years of revenues. We have a very strong industry position. We're the number one player in our industry, we have the largest footprint by any measure, we have the best reputation. When NASA wants a shirt, they come to us this should tell you something. What we need to scale now is MDK rents which we expect in the coming months. We expect to grow to 15 to 50 million in sales within four years from now, mostly from US healthcare services. We have a very strong team that has built and sold many med tech companies before we have a reputation for excellent service. We have dozens of advisors and many also running independent research programs with our products. I'm here today to announce that we're raising our Series A round to support our growth in US healthcare services. We already have $8 million in soft commitments and are looking for a lead investor for the round. Please join us so we can help millions of patients looking for better health access to post acute care. Join us to keep more patients healthy and at home. Please reach out to me for more information. I'll be in the breakout room. Thank you very much